文献速递肝病

门脉高压失代偿评分:一种经验证的预测模型

The Portal Hypertension Decompensation Score: A Validated Predictive Model of Liver Decompensation Related to Portal Hypertension.
PubMed 文献 · Am J Gastroenterol · 2025-08-22

本研究基于多中心队列开发并验证了门脉高压失代偿评分(PDS),用于预测代偿期进展性慢性肝病(cACLD)患者的失代偿风险。PDS仅使用血清标志物(胆红素、ALT、ALP、白蛋白、血小板),无需肝脏硬度测量,在验证队列中2年和5年预测失代偿的AUC分别为0.75和0.82、0.74和0.83。低分(< -3.348)对无失代偿的阴性预测值为91%-95%,高分(> -2.828)对未来失代偿的特异性为87%-93%。

要点

  • PDS仅基于5项血清标志物,无需肝脏硬度测量即可预测cACLD失代偿。
  • 验证队列中2年和5年预测失代偿的AUC分别为0.75/0.82和0.74/0.83。
  • 低分(< -3.348)阴性预测值91%-95%,高分(> -2.828)特异性87%-93%。

核心结论

  • PDS能准确预测cACLD患者的失代偿,区分低风险与高风险患者,且无需肝脏硬度测量。

研究设计与样本

  • 多中心全州队列研究,纳入2004-2015年cACLD患者,训练队列n=967,内部验证n=417,外部验证n=315(2017-2024年)。
  • 使用竞争风险分析开发基于血清标志物的预测评分,并与其它评分进行比较。

主要发现

  • 训练队列和两个验证队列的中位随访分别为3.2、3.4、1.9年,失代偿发生率分别为17.8%、15.3%、16.2%(P=0.60)。
  • 胆红素、ALT、ALP、白蛋白和血小板被纳入最终模型PDS,校准良好且区分度好。
  • 验证队列中PDS预测2年失代偿的AUC为0.75和0.82,5年为0.74和0.83。
  • 低分(< -3.348)预测无失代偿的敏感性为74%-84%,阴性预测值91%-95%。
  • 高分(> -2.828)预测未来失代偿的特异性为87%-93%,阳性预测值33%-58%。

关键数值与推荐

  • PDS低分阈值< -3.348,高分阈值> -2.828。
  • 验证队列中2年AUC 0.75和0.82,5年AUC 0.74和0.83。
  • 低分阴性预测值91%-95%,高分特异性87%-93%,阳性预测值33%-58%。

临床怎么用

  • 对于cACLD患者,可使用PDS基于血清标志物进行非侵入性风险分层,无需肝脏硬度测量。
  • 低分患者(< -3.348)失代偿风险低,可避免不必要的进一步评估。
  • 高分患者(> -2.828)失代偿风险较高,可能受益于进一步评估或治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is a need for noninvasive risk stratification in people with compensated advanced chronic liver disease (cACLD) to prognosticate and guide management. We aimed to develop a score that predicts decompensation in people with cACLD without the need for a liver stiffness measurement. METHODS: A multicenter state-wide cohort of patients with cACLD between 2004 and 2015 were followed until decompensation. A predictive score using serum markers was developed in a training cohort (n = 967) using competing risk analysis and internally validated (n = 417). Further external validation and comparison with other scores was undertaken in 315 patients between 2017 and 2024. RESULTS: Decompensation occurred in 172 (17.8%), 64 (15.3%), and 51 patients (16.2%) in the training and 2 validation cohorts ( P = 0.60) after median follow-up of 3.2, 3.4, and 1.9 years, respectively. Bilirubin, alanine aminotransferase, alkaline phosphatase, albumin, and platelets predicted decompensation and combined into a final model-the Portal Hypertension Decompensation Score (PDS). The PDS was well calibrated with good discrimination for predicting decompensation. In the 2 validation cohorts, accuracy (time-dependent area under the curve) of the PDS for predicting decompensation was high at 2 years (0.75 and 0.82) and 5 years (0.74 and 0.83). A low score (< -3.348) had a sensitivity of 74%-84% in prediction of no decompensation with a negative predictive value of 91%-95%, whereas a high score (> -2.828) was 87%-93% specific for future decompensation with a positive predictive value of 33%-58%. DISCUSSION: The PDS is an accurate predictor of decompensation in cACLD. It discriminates patients who are low risk from those who are high risk and who may benefit from further evaluation or treatment, without requiring the use of liver stiffness measurement.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Jeffrey AW, Majumdar A, Jeffrey G, et al. The Portal Hypertension Decompensation Score: A Validated Predictive Model of Liver Decompensation Related to Portal Hypertension. Am J Gastroenterol. 2025. PMID: 40844524. doi:10.14309/ajg.0000000000003744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。